CASI Pharmaceuticals - Aiming to be China’s hematology company
The year 2019 was transformational for CASI Pharmaceuticals. The company shifted its focus from in-licensing mature assets to investing in early-stage programs such as its CD19 CAR-T program CNCT19 and its anti-CD38 mAb CID-103. The company is focused on becoming a major provider of hematologic drugs for China. To this end, it plans to initiate four clinical trials in 2020 and two more in 2021. In this note we provide a comprehensive clinical and business outlook on the company.CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products. The company's primary product and candidates in hematology/oncology include: EVOMELA (Melphalan for Injection), an intravenous formulation of melphalan commercialized in the multiple myeloma treatment setting in the United States; CNCT19, which targets CD19, a B-cell surface protein expressed during all phases of B-cell development and a validated target for B-cell driven hematological malignancies; CID-103, an investigational anti-CD38 monoclonal antibody being developed for the treatment of patients with multiple myeloma.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.